文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

碳酸氢钠用于院内心脏骤停:一项随机临床试验

Sodium Bicarbonate for In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01
一句话结论在成人院内心脏骤停中,碳酸氢钠与安慰剂相比未显著提高持续自主循环恢复比例,作者认为结果不支持常规使用碳酸氢钠。

该研究为在丹麦21家医院开展的双盲、安慰剂对照随机临床试验,纳入院内心脏骤停且至少接受1剂肾上腺素的成人,比较碳酸氢钠(最多100 mmol)与安慰剂静脉给药。共913例随机,779例纳入主要分析(碳酸氢钠组372例,安慰剂组407例)。持续自主循环恢复在碳酸氢钠组146例(39%)、安慰剂组150例(37%),风险比1.05(95%CI 0.88-1.24),差异无统计学意义。30天生存率(12% vs 9.1%)及30天良好神经功能结局(8.1% vs 5.4%)差异均未达统计学显著;碳酸氢钠组心脏骤停后碱中毒和高钠血症更常见。作者结论为结果不支持对院内心脏骤停患者常规使用碳酸氢钠。

要点

  • 纳入成人院内心脏骤停且至少接受1剂肾上腺素者,随机接受碳酸氢钠(最多100 mmol)或安慰剂静脉给药。
  • 持续自主循环恢复:碳酸氢钠组39%(146/372)vs 安慰剂组37%(150/407),RR 1.05(95%CI 0.88-1.24),P=0.62,未达统计学显著。
  • 30天生存:碳酸氢钠组12%(45/372)vs 安慰剂组9.1%(37/407),RR 1.25(95%CI 0.84-1.88),未达统计学显著。
  • 30天良好神经功能结局(改良Rankin量表0-3分):碳酸氢钠组8.1%(30/372)vs 安慰剂组5.4%(22/407),RR 1.39(95%CI 0.82-2.34),未达统计学显著。
  • 碳酸氢钠组心脏骤停后碱中毒和高钠血症更常见;作者结论认为结果不支持对院内心脏骤停常规使用碳酸氢钠。

适用人群与场景

  • 丹麦21家医院内发生院内心脏骤停的成人患者,且至少接受1剂肾上腺素。

处置流程与药物剂量

  • 干预为碳酸氢钠(最多100 mmol)或安慰剂静脉给药,具体给药频次与疗程原文未写明。

研究设计与关键结果

  • 研究类型为随机、平行分组、双盲、安慰剂对照临床试验,在丹麦21家医院开展;筛查2913例院内心脏骤停患者,913例随机,779例纳入主要分析(碳酸氢钠组372例,安慰剂组407例)。
  • 患者中位年龄73岁(IQR 64-79),男性502例(64%)。
  • 主要终点持续自主循环恢复:碳酸氢钠组146例(39%)vs 安慰剂组150例(37%),RR 1.05(95%CI 0.88-1.24),P=0.62。
  • 30天生存:碳酸氢钠组45例(12%)vs 安慰剂组37例(9.1%),RR 1.25(95%CI 0.84-1.88)。
  • 30天良好神经功能结局(改良Rankin量表0-3分):碳酸氢钠组30例(8.1%)vs 安慰剂组22例(5.4%),RR 1.39(95%CI 0.82-2.34)。
  • 不良事件:心脏骤停后碱中毒和高钠血症在碳酸氢钠组更常见。

证据类型、等级与局限

  • 证据类型为随机、双盲、安慰剂对照临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在成人院内心脏骤停中碳酸氢钠与安慰剂在持续自主循环恢复上无显著差异,这些发现不支持对院内心脏骤停患者常规使用碳酸氢钠。
  • 碳酸氢钠组心脏骤停后碱中毒和高钠血症更常见。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patients with in-hospital cardiac arrest have poor outcomes. Sodium bicarbonate is commonly administered during cardiac arrest, but the effects on clinical outcomes are unknown.

OBJECTIVE: To determine whether administration of sodium bicarbonate during in-hospital cardiac arrest increases the proportion of patients with return of spontaneous circulation.

DESIGN, SETTING, AND PARTICIPANTS: Randomized, parallel-group, double-blind, placebo-controlled clinical trial conducted at 21 hospitals in Denmark. Participants were adults with in-hospital cardiac arrest, who received at least 1 dose of epinephrine. Patients were enrolled from February 6, 2023, to February 11, 2026, with the last 90-day follow-up conducted on May 4, 2026. Final statistical analysis was conducted on May 5, 2026.

INTERVENTION: Sodium bicarbonate (up to 100 mmol) or placebo intravenously.

MAIN OUTCOMES AND MEASURES: The primary outcome was sustained return of spontaneous circulation. Key secondary outcomes were survival at 30 days and survival at 30 days with a favorable neurologic outcome, defined by a score of 0 to 3 on the modified Rankin Scale (scores range from 0 to 6, with higher scores indicating greater disability).

RESULTS: A total of 2913 patients with in-hospital cardiac arrest were screened; 913 patients were randomized, of which 779 were eligible for the primary analyses, with 372 randomized to receive sodium bicarbonate and 407 randomized to receive placebo. The median (IQR) age of patients was 73 (64-79) years and 502 were male (64%). Sustained return of spontaneous circulation occurred in 146 patients (39%) in the sodium bicarbonate group and 150 (37%) in the placebo group (risk ratio, 1.05 [95% CI, 0.88-1.24]; P = .62). At 30 days, 45 patients (12%) in the sodium bicarbonate group and 37 (9.1%) in the placebo group were alive (risk ratio, 1.25 [95% CI, 0.84-1.88]); a favorable neurologic outcome at 30 days occurred in 30 patients (8.1%) and 22 patients (5.4%), respectively (risk ratio, 1.39 [95% CI, 0.82-2.34]). Alkalosis and hypernatremia after cardiac arrest were more common in the sodium bicarbonate group.

CONCLUSIONS AND RELEVANCE: There was no significant difference in sustained return of spontaneous circulation between sodium bicarbonate and placebo in adults with in-hospital cardiac arrest. These findings do not support routine administration of sodium bicarbonate for patients with in-hospital cardiac arrest.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05564130; ClinicalTrialsRegister.eu Identifier: 2022-501304-10-00.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Granfeldt A, Kirkegaard BL, Vallentin MF, et al. Sodium Bicarbonate for In-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2026. PMID: 42273960. doi:10.1001/jama.2026.10628

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。